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Featured Application: Inhibition of Tdp1 has the potential to increase the potency of the anticancer
drugs topotecan and irinotecan, topoisomerase 1 poisons. Furthermore, Tdp1 inhibitors can
facilitate the therapeutic use of these drugs in other cancer types.
Abstract: Eleven amide and thioamide derivatives with monoterpene and adamantine substituents
were synthesised. They were tested for their activity against the tyrosyl-DNA phosphodiesterase
1 DNA (Tdp1) repair enzyme with the most potent compound 47a, having an IC50 value of 0.64
µM. When tested in the A-549 lung adenocarcinoma cell line, no or very limited cytotoxic effect was
observed for the ligands. However, in conjunction with topotecan, a well-established Topoisomerase
1 (Top1) poison in clinical use against cancer, derivative 46a was very cytotoxic at 5 µM concentration,
displaying strong synergism. This effect was only seen for 46a (IC50—3.3 µM) albeit some other
ligands had better IC50 values. Molecular modelling into the catalytic site of Tdp1 predicted plausible
binding mode of 46a, effectively blocking access to the catalytic site.
Keywords: topotecan; A-549 lung adenocarcinoma cell line l; Topoisomerase 1; molecular modelling;
chemical space; synergy; thermal shift assay; intrinsic tryptophan fluorescence binding assay;
fluorescence biosensor assay
1. Introduction
Camptothecin derivatives (CPTs) such as topotecan, irinotecan and belotecan are common
chemotherapy agents that are used for the treatment of cancers. These therapeutic agents are used
either as monotherapy or in combination with other anticancer drugs for the treatments of small cell
lung cancer, metastatic colon and rectal carcinoma [1,2]. Belotecan was recently approved in South
Korea for non-small-cell lung cancer and ovarian cancer [2].
Appl. Sci. 2019, 9, 2767; doi:10.3390/app9132767 www.mdpi.com/journal/applsci
Appl. Sci. 2019, 9, 2767 2 of 18
The target of CPTs is topoisomerase I (TOP1) [3]. TOP1 plays an essential role during transcription,
replication and repair of DNA by resolving helical duplex DNA topological problems. First, the
enzyme forms a complex with double-strand DNA, a tyrosine residue at the TOP1 active site then
introduces a single-strand break by catalysing the formation of a 3’-tyrosyl-phosphodiester bond,
leading to the covalent linking of TOP1 and the 3’-phosphoryl end of the DNA. After rotation of the
5’-DNA end around the non-cleaved strand, the integrity of the DNA is restored, which is then followed
by enzyme dissociation [4]. Binding of CPTs with the transient TOP1–DNA complex inhibits TOP1
dissociation, which subsequently leads to the formation of irreversible covalently-bound TOP1–DNA
complexes, thus blocking replication and transcription [5]. The accumulation of DNA lesions halts
cellular processes and results in cell death.
Repair enzymes such as tyrosyl-DNA phosphodiesterase (Tdp1), 3’-flap endonucleases, and base
excision repair (BER) complexes cleave covalent TOP1–DNA complexes, thus initiating DNA integrity
recovery. The Tdp1 enzyme hydrolyses the 3’-phosphotyrosyl bond between single-strand DNA and
TOP1, which is formed as a result of TOP1 hydrolysis catalysed by proteases. In addition, Tdp1 is
involved in the elimination of other lesions at the 3’-end of DNA, for example, 3’-phosphoglycolate,
and repair of apurinic/apyrimidinic sites generated by oxidative and free radical DNA damage [6–8].
Therefore, in the context of the molecular mechanism of CPTs, Tdp1 catalyses the dissociation of the
TOP1–DNA complexes that are trapped by CPTs and; therefore, eliminating the therapeutic effect
of TOP1 poisons. Moreover, Tdp1 activity was found to cause drug resistance of some cancer cell
lines [9–11] and Tdp1 knockout cells were demonstrated to show increased sensitivity to CPT [12] and
irinotecan [10]. Thus, enhancing anticancer the therapeutic effect can be achieved with the simultaneous
administration of CPTs and Tdp1 inhibitors [13]. Furthermore, Tdp1 inhibition can lead to synergistic
effect with anticancer agents with other mechanisms of action, including bleomycin and its derivatives
as well as monofunctional alkylating agents or even radiotherapy [14,15].
A wealth of Tdp1 inhibitors have been identified so far with various molecular scaffolds
(see Figure 1) and potency down to nano-molar activity [16–40].
It is known that monoterpene derivatives have various biological activities [41]. Interestingly,
potent Tdp1 inhibitory activity was obtained for citral, citronellal and perillaldehyde derivatives of
usnic acid, citronellal derivative 17 with IC50 = 0.43 µM) [34] and 7-hydroxycoumarin, most potent
being 18 with IC50 = 0.33 µM, the structures are shown in Figure 2. Furthermore, derivative 18 had
synergistic effect with CPT, 18 increasing CPT cytotoxicity eight-fold in the breast adenocarcinoma
MCF-7 cell line [42]. Monoterpene derivatives of substituted anilines were found to be active at
low micromolar concentrations (IC50 = 1.29 µM) for 19 and for 20 (IC50 = 0.79 µM) (Figure 2) [43].
Additionally, potent inhibitory activity was found for derivatives containing adamantane. Bile acid
amide 21 inhibited Tdp1 with IC50 = 0.47 µM [44], whilst octahydro-2H-chromen-4-ol derivative
22 IC50 was 1.24 µM (see Figure 2) [45]. It was also demonstrated that compounds combining
adamantane/heteroadamantane and monoterpene fragments are active against Tdp1 [46,47]. Moderate
activity at micromolar concentrations (IC50~15µM) was demonstrated for diazaadamantanes containing
citronellal and citral moieties 23 and 24 (Figure 2) [46]. The adamantane derivatives 25 and 26 (Figure 2)
had activity at IC50 = 6.0 and 3.5 µM, respectively [47]. A synergistic effect was found for the
simultaneous action of 25 or 26 and topotecan. Derivative 26 increased cytotoxic effect of topotecan
five-fold whilst 25 increased cytotoxicity two-fold in the colon carcinoma HCT-116 cell line [47].
Monoterpene derivatives of 1- and 2-aminoadamantane 27 and 28 decreased Tdp1 activity by 50% at
6.6 and 5.5 µM, respectively [48].
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Figure 2. Monoterpenes and adamantane/diazaadmanatane derivatives with Tdp1 inhibitory activity.
Previously we synthesized a number of esters of 1-adamantane carboxylic acid containing
fragments of acyclic, monocyclic and bicyclic monoterpenoids. A potent Tdp1 inhibitory activity
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with IC50 ranging from 0.9 to 4 µM was achieved [49]. It was found that acyclic derivatives 29
(IC50 = 0.89 µM) and 30 (IC50 = 0.92 µM) are in Figure 2) had more potent activity than monocyclic or
bicyclic derivatives. Additionally, ester 29 increased topotecan cytotoxicity [49]. Drugs containing the
ester moiety often have metabolic instability due to hydrolysis by carboxylesterases [50]. To mitigate
this problem, amides can be used. Therefore, we investigated the substitution of esters by amides and
thioamides in combining adamantane and acyclic monoterpene fragments on Tdp1 inhibitory activity.
2. Materials and Methods
2.1. Chemistry
Adamantane 1-carbonyl chloride (97%), nerol (97%) and trimethylsulfoxonium iodide (98%) were
purchased from Acros organics; 3,7-dymethiloctanol (≥98%) and boron trifluoride diethyl etherate were
purchased from Sigma-Aldrich; citronellic acid (94%) was purchased from Alfa Aesar; adamantan-2-one
(≥99%) was purchased from Merck. Toluene was freshly distilled under sodium before use. Column
chromatography was performed with silica gel (60–230 µ, Macherey-Nagel), solution containing from
0% to 5% ethyl acetate in hexane. 1H- and 13C-NMR spectra were registered on a Bruker Avance—III
600 spectrometer (600.30 MHz (1H) and 150.95 MHz (13C) in CDCl3). Chemical shifts obtained are
given in ppm, relative to residual chloroform (δH 7.24 ppm, δC 76.90 ppm), and J are given in Hz.
The structures of the products were determined by analyzing their 1H NMR spectra, J-modulated
13C NMR spectra (JMOD), 13C - 1H-type 2D heteronuclear correlation with one bond (HSQC, 1J 145
Hz) and long-range spin–spin coupling constants (HMBC, 2,3J 7 Hz) and 1H - 1H double-resonance
spectra (COSY, NOESY). Numeration of atoms in the compounds (see Supplementary Materials,
Figures S7–S15) is given for assigning the signals in the NMR spectra and does not coincide with
the nomenclature of the compounds. The elemental composition of compounds was determined
from high-resolution mass spectra (HR-MS) recorded on a DFS Thermo Scientific spectrometer in full
scan mode (0–500 m/z, 70 eV electron impact ionization, direct sample injection). The conversion of
reagents, the content of the compounds in fractions during chromatography and the purity of the
target compounds was determined using gas chromatography methods: 7820A gas chromatograph
(Agilent Tech., USA), flame-ionization detector, HP-5 capillary column (0.25 mm × 3 m × 0.25 µm),
helium carrier gas (flow rate 2 mL/min, flow division 99:1), temperature range from 120 to 280 ◦C,
heating 20 ◦C/min. The purity of the target compounds for biological testing was confirmed to be more
than 95%.
2.1.1. Synthesis of Amines 36, 37
Bromides 40, 41 were synthesized from 3,7-dimethyloctanol 38 and nerol 39 (1.0 g, 6.5 mmol,
2.5 eq) by stirring of with PBr3 (0.24 mL, 2.6 mmol, 1 eq) in diethyl ether (38) and THF (39) solutions
(10 mL of each solvents) at cooling according to the methods [42,51]. Then, the derivatives 40, 41
obtained were used without further purification. To solution 40 and 41 (1.2 g, 5.4 mmol, 1 eq) in dry
DMF (40 mL) potassium phthalimide (1.0 g, 5.4 mmol, 1 eq) was added, the reaction mixture was
stirred at 50 ◦C until the reaction completed, treated with water (100 mL) and extracted by CHCl3.
The extract was washed by 5% NaOH solution (50 mL), brine (50 mL) and evaporated with water and
toluene consequentially. Resulted residues were purified by column chromatography with yielding
phthalimides 42 (1.3 g, 4.5 mmol, yield 95%) and 43 (1.1 g, 4.0 mmol, yield 74%). To solution of 42 and
43 (1.1 g, 4.0 mmol, 1 eq) in methanol (30 mL), ethylenediamine (0.53 mL, 8.0 mmol, 2 eq) was added,
the mixture was refluxed until the reaction completed, treated with water (30 mL) and extracted by
Et2O. The organic layer was washed by 5% NaOH (30 mL), brine (30 mL) and dried under Na2SO4.
The solvent was evaporated and hexane (30 mL) was added to the residue. The solution was filtered
and the solvent was distilled off yielding 36 (0.34 g, 2.4 mmol, yield 55%) and 37 (0.57 g, 3.7 mmol,
yield 94%).
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2.1.2. General Procedure for Amides 44a,b; 45a,b; 50a,b
Citronellic acid (0.30 g, 1.7 mmol, 1 eq) was previously refluxed with thionyl chloride (0.25 mL, 3.5
mmol, 2 eq) in toluene (15 mL) 2 h. The solvent was distilled off and the citronellic acid chloride 48 was
obtained (0.32 g, 1.7 mmol, yield 98%). To solution of carboxylic acid chlorides 31, 32 (0.16 g, 0.79 mmol,
1 eq), 48 (0.15 g, 0.79 mmol, 1 eq) in dry toluene (20 mL) amines 36, 37 (0.12 g, 0.79 mmol, 1 eq), as
well as 1- and 2-aminoadamantanes 49a,b (0.12 g, 0.79 mmol, 1 eq) and trimethylamine (0.11 mL, 0.79
mmol, 1 eq) were added at 0 ◦C. The mixtures were stirred overnight at room temperature, evaporated,
dissolved in EtOAc (30 mL), washed by 5% NaOH (20 mL), brine (20 mL) and dried with Na2SO4.
The solvent was distilled off under reduced pressure and the solid obtained was purified by column
chromatography yielding amides 44a,b; 45a,b; 50a,b.
2.1.3. N-(3,7-Dimethyloctyl)adamantane-1-carboxamide 44a
Yield 85%. 1H-NMR (CDCl3): 0.83 d (6H, J(20, 19) = J(21, 19) = 6.6 Hz, 3H-20, 3H-21), 0.86 d
(3H, J(22, 15) = 6.6 Hz, 3H-22), 1.04–1.14 m (3H, H-16, 2H-18), 1.17–1.30 m (4H, H′-14, H′-16, 2H-17),
1.37-1.52 m (3H, H′-14, H-15, H-19), 1.63–1.73 m (6H, 2H-4, 2H-6, 2H-10), 1.81 d (6H, 3J = 3.0 Hz, 2H-2,
2H-8, 2H-9), 1.98–2.03 m (3H, H-3, H-5, H-7), 3.15–3.28 m (2H, 2H-13), 5.50 br. s (1H, NH). 13C-NMR
(CDCl3): 40.39 (s, C-1), 39.18 (t, C-2, C-8, C-9), 28.03 (d, C-3, C-5, C-7), 36.42 (t, C-4, C-6, C-10), 177.66
(s, C-11), 37.33 (t, C-13), 36.59 (t, C-14), 30.59 (d, C-15), 36.99 (t, C-16), 24.52 (t, C-17), 39.07 (t, C-18),
27.81 (d, C-19), 22.47, 22.56 (2q, C-20, C-21), 19.46 (q, C-22). HR MS: 319.2871 ([M]+, C21H37O1N1+;
calc. 319.2870).
2.1.4. N-((Z)-3,7-Dimethylocta-2,6-dien-1-yl)adamantane-1-carboxamide 44b
Yield 43%. 1H-NMR (CDCl3): 1.58 br. s (3H, 3H-21), 1.64–1.74 m (6H, 2H-4, 2H-6, 2H-10), 1.66 br.
s (3H, 3H-20), 1.70 br. s (3H, 3H-22), 1.82 d (6H, 3J = 3.0 Hz, 2H-2, 2H-8, 2H-9), 1.98–2.08 m (7H, H-3,
H-5, H-7, 2H-16, 2H-17), 3.78 br. t (2H, J(13, 14) ≈ 7.1 Hz, 2H-13), 5.03–5.08 m (1H, H-18), 5.16 tm (1H,
J(14, 13) = 7.1 Hz, H-14), 5.40 br. s (1H, NH). 13C-NMR (CDCl3): 40.40 (s, C-1), 39.15 (t, C-2, C-8, C-9),
28.03 (d, C-3, C-5, C-7), 36.42 (t, C-4, C-6, C-10), 177.61 (s, C-11), 37.06 (t, C-13), 120.87 (d, C-14), 140.01
(s, C-15), 31.85 (t, C-16), 26.46 (t, C-17), 123.53 (d, C-18), 131.99 (s, C-19), 25.63 (q, C-20), 17.58 (q, C-21),
23.27 (q, C-22). HR MS: 315.2551 ([M]+, C21H33O1N1+; calc. 315.2557).
2.1.5. N-(3,7-Dimethyloctyl)adamantane-2-carboxamide 45a
Yield 54%. 1H-NMR (CDCl3): 0.83 d (6H, J(20, 19) = J(21, 19) = 6.6 Hz, 3H-20, 3H-21), 0.87 d
(3H, J(22, 15) = 6.6 Hz, 3H-22), 1.05–1.13 m (3H, H-16, 2H-18), 1.17–1.32 m (4H, H-14, H′-16, 2H-17),
1.38–1.52 m (3H, H′-14, H-15, H-19), 1.56–1.61 br. d (2H, 2J ≈ 12.5 Hz, H-4, H-9), 1.68–1.77 m (4H,
2H-6, H-8, H-10), 1.79–1.83 m (1H, H-5 or H-7), 1.83–1.93 m (5H, H′-4, H-7 or H-5, H′-8, H′-9, H′-10),
2.20–2.25 m (2H, H-1, H-3), 2.41 br. s (1H, H-2), 3.21–3.34 m (2H, 2H-13), 5.55 br. s (1H, NH). 13C-NMR
(CDCl3): 29.88, 29.89 (2d, C-1, C-3), 49.87 (d, C-2), 33.19 (t, C-4, C-9), 27.28, 27.37 (2d, C-5, C-7), 37.26 (t,
C-6), 38.25 (t, C-8, C-10), 173.81 (s, C-11), 37.32 (t, C-13), 36.76 (t, C-14), 30.59 (d, C-15), 37.00 (t, C-16),
24.54 (t, C-17), 39.07 (t, C-18), 27.81 (d, C-19), 22.46, 22.55 (2q, C-20, C-21), 19.40 (q, C-22). HR MS:
319.2873 ([M]+, C21H37O1N1+; calc. 319.2870).
2.1.6. N-((Z)-3,7-Dimethylocta-2,6-dien-1-yl)adamantane-2-carboxamide 45b
Yield 43%. 1H-NMR (CDCl3): 1.57–1.62 m (2H, H-4, H-9), 1.58 m (3H, all J < 1.5 Hz, 3H-21), 1.66
m (3H, all J < 1.5 Hz, 3H-20), 1.69–1.75 m (4H, 2H-6, H-8, H-10), 1.70 m (3H, all J < 2.0 Hz, 3H-22),
1.79–1.95 m (6H, H′-4, H-5, H-7, H′-8, H′-9, H′-10), 2.01–2.09 m (4H, 2H-16, 2H-17), 2.20–2.25 m (2H,
H-1, H-3), 2.40–2.43 m (1H, H-2), 3.82–3.86 m (2H, 2H-13), 5.03–5.08 m (1H, H-18), 5.18 tm (1H, J(14, 13)
= 7.2 Hz, H-14), 5.41 br. s (1H, NH). 13C-NMR (CDCl3): 29.89 (d, C-1, C-3), 49.89 (d, C-2), 33.19 (t, C-4,
C-9), 27.29, 27.39 (2d, C-5, C-7), 37.28 (t, C-6), 38.26 (t, C-8, C-10), 173.70 (s, C-11), 36.99 (t, C-13), 121.01
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(d, C-14), 139.81 (s, C-15), 31.83 (t, C-16), 26.41 (t, C-17), 123.57 (d, C-18), 131.98 (s, C-19), 25.57 (q, C-20),
17.56 (q, C-21), 23.24 (q, C-22). HR MS: 315.2553 ([M]+, C21H33O1N1+; calc. 315.2557).
2.1.7. N-(Adamantan-1-yl)-3,7-dimethyloct-6-enamide 50a
Yield 70%. 1H-NMR (CDCl3): 0.90 d (3H, J(21, 14) = 6.6 Hz, 3H-21), 1.11–1.20 m (1H, H-15),
1.29–1.37 m (1H, H′-15), 1.57 br. s (3H, 3H-20), 1.61–1.68 m (9H, 2H-4, 2H-6, 2H-10, 3H-19), 1.81 dd (1H,
2J = 13.6 Hz, J(13, 14) = 8.4 Hz, H-13), 1.87–2.02 m (9H, H-14, 2H-16, 2H-2, 2H-8, 2H-9), 2.02–2.06 m
(3H, H-3, H-5, H-7), 2.09 dd (1H, 2J = 13.6 Hz, J(13’, 14) = 5.9 Hz, H′-13), 5.06 tm (1H, J(17, 16) = 7.2 Hz,
H-17), 5.20 br. s (1H, H-11). 13C-NMR (CDCl3): 51.81 (s, C-1), 41.56 (t, C-2, C-8, C-9), 29.32 (d, C-3, C-5,
C-7), 36.24 (t, C-4, C-6, C-10), 171.79 (s, C-12), 45.35 (t, C-13), 30.46 (d, C-14), 36.73 (t, C-15), 25.34 (t,
C-16), 124.33 (d, C-17), 131.29 (s, C-18), 25.58 (q, C-19), 17.54 (q, C-20), 19.31 (q, C-21). HR MS: 303.2558
([M]+, C20H33O1N1+; calc. 303.2557).
2.1.8. N-(Adamantan-2-yl)-3,7-dimethyloct-6-enamide 50b
Yield 72%. 1H-NMR (CDCl3): 0.92 d (3H, J(21, 14) = 6.6 Hz, 3H-21), 1.15–1.22 m (1H, H-15),
1.32–1.39 m (1H, H′-15), 1.57 br. s (3H, 3H-20), 1.60–1.65 m (2H, H-4, H-9), 1.65 m (3H, all J < 2.0 Hz,
3H-19), 1.70–1.76 m (4H, H′-4, 2H-6, H′-9), 1.77–1.85 m (6H, H-5, H-7, 2H-8, 2H-10), 1.86–1.90 m (2H,
H-1, H-3), 1.90–2.05 m (4H, H-13, H-14, 2H-16), 2.15–2.22 m (1H, H′-13), 4.03–4.06 m (1H, H-2), 5.06 tm
(1H, J(17, 16) = 7.2 Hz, H-17), 5.70 br. d (1H, J(11, 2) ≈ 8.0 Hz, NH). 13C-NMR (CDCl3): 31.82, 31.86 (2d,
C-1, C-3), 52.90 (d, C-2), 31.85 (t, C-4, C-9), 27.01, 27.12 (2d, C-5, C-7), 37.43 (t, C-6), 36.98, 37.01 (2t, C-8,
C-10), 171.41 (s, C-12), 44.87 (t, C-13), 30.55 (d, C-14), 36.79 (t, C-15), 25.34 (t, C-16), 124.26 (d, C-17),
131.37 (s, C-18), 25.58 (q, C-19), 17.54 (q, C-20), 19.41 (q, C-21). HR MS: 303.2562 ([M]+, C20H33O1N1+;
calc. 303.2557).
2.1.9. General Procedure for Thioamides 46a,b; 47a,b; 51
To the solution of amides 44a,b; 45a,b (53 mg, 0.16 mmol, 1 eq), 50b (50 mg, 0.16 mmol, 1 eq) in dry
toluene (10 mL), Py (6.6 µL, 82 µmol, 0.5 eq) and Lawesson’s reagent (0.20, 0.49 mmol, 3 eq) were added,
the mixture was refluxed overnight in argon atmosphere [52]. The solvent was evaporated, the residue
was dissolved in Et2O and washed with saturated solution of NaHCO3 (20 mL) and brine (20 mL)
consequentially and dried with Na2SO4. Thioamides were purified by column chromatography.
2.1.10. N-(3,7-Dimethyloctyl)adamantane-1-carbothioamide 46a
Yield 88%. 1H-NMR (CDCl3): 0.84 d (6H, J(20, 19) = J(21, 19) = 6.6 Hz, 3H-20, 3H-21), 0.91 d (3H,
J(22, 15) = 6.5 Hz, 3H-22), 1.07–1.17 m (3H, H-16, 2H-18), 1.18–1.32 m (3H, H′-16, 2H-17), 1.40–1.54 m
(3H, H-14, H-15, H19), 1.61–1.74 m (7H, 2H-4, 2H-6, 2H-10, H′-14), 1.94 d (6H, 3J = 3.0 Hz, 2H-2, 2H-8,
2H-9), 2.04–2.09 m (3H, H-3, H-5, H-7), 3.60–3.71 m (2H, 2H-13). 13C-NMR (CDCl3): 45.79 (s, C-1),
41.74 (t, C-2, C-8, C-9), 28.49 (d, C-3, C-5, C-7), 36.30 (t, C-4, C-6, C-10), 212.60 (s, C-11), 44.32 (t, C-13),
34.92 (t, C-14), 30.88 (d, C-15), 36.92 (t, C-16), 24.52 (t, C-17), 39.04 (t, C-18), 27.81 (d, C-19), 22.45, 22.55
(2q, C-20, C-21), 19.54 (q, C-22). HR MS: 335.2638 ([M]+, C21H37N1S1+; calc. 335.2641).
2.1.11. N-((Z)-3,7-Dimethylocta-2,6-dien-1-yl)adamantane-1-carbothioamide 46b
Yield 31%. A NMR spectra of trans- and cis-isomers at C-14-C-15 bond was obtained for their
mixture in ratio ≈ 1.0:0.8, respectively. In 1H-NMR spectrum the signals of corresponding protons
of isomers superimpose on each other. In 13C-NMR spectrum, most of the carbon signals of both
isomers differ. 1H-NMR (CDCl3): 1.57 br. s (3H-21 of both isomers), 1.63–1.74 m (2H-4, 2H-6, 2H-10 of
both isomers), 1.65 m (3H-20 of both isomers, 3H-22 of trans-isomer), 1.72 m (3H-22 of cis-isomer),
1.92–1.95 m (2H-2, 2H-8, 2H-9 of both isomers), 1.98–2.12 m (H-3, H-5, H-7, 2H-16, 2H-17 of both
isomers), 4.14–4.19 m (2H-13 of both isomers), 5.01–5.06 m (H-18 of both isomers), 5.26–5.31 m (H-14 of
both isomers), 7.09 br. s (NH of both isomers). 13C-NMR of trans-isomer (CDCl3): 45.69 (s, C-1), 41.69
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(t, C-2, C-8, C-9), 28.45 (d, C-3, C-5), 36.25 (t, C-4, C-6, C-10), 212.19 (s, C-11), 44.35 (t, C-13), 117.84 (d,
C-14), 142.31 (s, C-15), 39.27 (t, C-16), 26.10 (t, C-17), 123.48 (d, C-18), 131.71 (s, C-19), 25.52 (q, C-20),
17.56 (q, C-21), 16.38 (q, C-22). 13C-NMR of cis-isomer (CDCl3): 45.68 (s, C-1), 41.69 (t, C-2, C-8, C-9),
28.45 (d, C-3, C-5, C-7), 36.25 (t, C-4, C-6, C-10), 212.22 (s, C-11), 44.13 (t, C-13), 118.57 (d, C-14), 142.52
(s, C-15), 31.96 (t, C-16), 26.39 (t, C-17), 123.24 (d, C-18), 132.14 (s, C-19), 25.56 (q, C-20), 17.58 (q, C-21),
23.25 (q, C-22). HR MS: 330.2249 ([M]+, C21H33N1S1+; calc. 331.2328).
2.1.12. N-(3,7-Dimethyloctyl)adamantane-2-carbothioamide 47a
Yield 87%. 1H-NMR (CDCl3): 0.83 d (6H, J(20, 19) = J(21, 19) = 6.6 Hz, 3H-20, 3H-21), 0.91 d (3H,
J(22, 15) = 6.5 Hz, 3H-22), 1.07–1.17 m (3H, H-16, 2H-18), 1.18–1.33 m (3H, H′-16, 2H-17), 1.41–1.53 m
(3H, H-14, H-15, H-19), 1.56–1.62 m (2H, H-4, H-9), 1.63–1.70 m (1H, H′-14), 1.70–1.73 m (2H, 2H-6),
1.76–1.94 m (8H, H′-4, H-5, H-7, 2H-8, H′-9, 2H-10), 2.60–2.63 m (2H, H-1, H-3), 2.65–2.69 m (1H, H-2),
3.67–3.79 m (2H, H-13), 7.34 br. s (1H, NH). 13C-NMR (CDCl3): 31.41, 31.42 (2d, C-1, C-3), 56.15 (d, C-2),
32.56 (t, C-4, C-9), 27.11, 27.25 (2d, C-5, C-7), 37.09 (t, C-6), 38.40 (t, C-8, C-10), 206.53 (s, C-11), 44.32 (t,
C-13), 35.00 (t, C-14), 30.85 (d, C-15), 36.89 (t, C-16), 24.53 (t, C-17), 39.01 (t, C-18), 27.80 (d, C-19), 22.44,
22.54 (2q, C-20, C-21), 19.47 (q, C-22). HR MS: 335.2637 ([M]+, C21H37N1S1+; calc. 335.2641).
2.1.13. N-((Z)-3,7-Dimethylocta-2,6-dien-1-yl)adamantane-2-carbothioamide 47b
Yield 60%. 1H-NMR (CDCl3): 1.57–1.62 m (2H, H-4, H-9), 1.58 br. s (3H, 3H-21), 1.66 m (3H, all J <
1.5 Hz, 3H-20), 1.70–1.73 m (2H, 2H-6), 1.75 m (3H, all J < 2.0 Hz, 3H-22), 1.76–1.95 m (8H, H′-4, H-5,
H-7, 2H-8, 2H-10, H′-9), 2.02–2.12 m (4H, 2H-16, 2H-17), 2.60–2.63 m (2H, H-1, H-3), 2.65–2.68 m (1H,
H-2), 4.23–4.27 m (2H, 2H-13), 5.03–5.08 m (1H, H-18), 5.31 tm (1H, J(14, 13) = 7.1 Hz, H-14), 7.17 br. s
(1H, NH). 13C-NMR (CDCl3): 31.42 (d, C-1, C-3), 56.06 (d, C-2), 32.59 (t, C-4, C-9), 27.14, 27.29 (2d, C-5,
C-7), 37.15 (t, C-6), 38.43 (t, C-8, C-10), 206.22 (s, C-11), 44.22 (t, C-13), 118.56 (d, C-14), 142.59 (s, C-15),
32.03 (t, C-16), 26.42 (t, C-17), 123.29 (d, C-18), 132.27 (s, C-19), 25.57 (q, C-20), 17.60 (q, C-21), 23.30 (q,
C-22). HR MS: 330.2245 ([M]+, C21H33N1S1+; calc. 331.2328).
2.1.14. N-(Adamantan-2-yl)-3,7-dimethyloct-6-enethioamide 51
Yield 64%. 1H-NMR (CDCl3): 0.90 d (3H, J(21, 14) = 6.7 Hz, 3H-21), 1.13–1.21 m (1H, H-15),
1.33–1.40 m (1H, H′-15), 1.56 br. s (3H, 3H-20), 1.64 br. s (3H, 3H-19), 1.68–1.72 m (4H, 2H-9, 2H-10),
1.72–1.76 m (2H, 2H-6), 1.82–1.85 m (4H, 2H-4, 2H-8), 1.85–1.89 m (2H, H-5, H-7), 1.91–2.05 m (2H,
2H-16), 2.08–2.16 m (3H, H-1, H-3, H-14), 2.37 dd (1H, 2J = 13.1 Hz, J(13, 14) = 8.4 Hz, H-13), 2.67 dd
(1H, 2J = 13.1 Hz, J(13′, 14) = 6.2 Hz, H′-13), 4.56 ddd (1H, J(2, NH) = 8 Hz, J(2, 1) ≈ J(2, 3) ≈ 3.0 Hz,
H-2), 5.05 tm (1H, J(17, 16) = 7.1 Hz, other J < 2.0 Hz, H-17), 7.40 br. d (1H, J(NH, 2) = 8 Hz, NH).
13C-NMR (CDCl3): 30.47, 30.49 (2d, C-1, C-3), 58.84 (d, C-2), 36.67, 36.71 (2t, C-4, C-8), 26.89 (d, C-5,
C-7), 37.20 (t, C-6), 32.24 (t, C-9, C-10), 202.97 (s, C-12), 55.52 (t, C-13), 33.45 (d, C-14), 36.34 (t, C-15),
25.28 (t, C-16), 124.09 (d, C-17), 131.43 (s, C-18), 25.55 (q, C-19), 17.53 (q, C-20), 18.75 (q, C-21). HR MS:
319.2327 ([M]+, C21H33N1S1+; calc. 319.2328).
2.2. Modelling and Screening
The compounds were docked against the crystal structure of Tdp1 PDB ID: 1MU7, resolution
2.0 Å) [53] which was obtained from the Protein Data Bank (PDB, Cambridge, UK) [54,55]. The Scigress
version FJ 2.6 program [56] was used to prepare the crystal structure for docking (i.e., the hydrogen
atoms were added, the co-crystallised tungsten(VI)ion was removed as well as crystallographic water
molecules). For further studies, HOH631 and HOH832 water molecules were kept in the crystal
structure. The Scigress software suite was also used to build the inhibitors and the MM2 [57] force field
was used to optimise the structures. The docking centre was defined as the position of the hydrogen
atom of His263, whereby nitrogen formed a coordination bond with the tungsten ion (x = 7.319,
y = 0.055, z = 96.688) with 10 Å radius. Fifty docking runs were allowed for each ligand with default
search efficiency (100%). The basic amino acids lysine and arginine were defined as protonated.
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Furthermore, aspartic and glutamic acids were assumed deprotonated. The GoldScore(GS) [58] and
ChemScore(CS) [59,60], Piecewise Linear Potential (ChemPLP) [61] and Astex Statistical Potential
(ASP) [62] scoring functions were implemented to validate the predicted binding modes and relative
energies of the ligands using the GOLD v5.4.1 software suite. The QikProp 3.2 [63] software package
was used to calculate the molecular descriptors of the molecules. The reliability of it is established for
the calculated descriptors [64].
2.3. Biological Study
2.3.1. TDP1 Activity
A fluorophore quencher-coupled DNA-biosensor for real-time measurement of Tdp1 cleavage
activity was designed recently in our laboratory [29]. This biosensor is a short single-stranded
oligonucleotide with a 5′-FAM fluorophore and a 3′-BHQ1 (black hole quencher 1) quencher.
Recombinant protein Tdp1 was expressed in Escherichia coli (pET 16B plasmid containing Tdp1
cDNA was provided by Dr. K.W. Caldecott, University of Sussex, United Kingdom) and isolated as
described [7,65]. The reaction mixture in a final volume 200 µL contained Tdp1 reaction buffer (50 mM
Tris-HCl, 50 mM NaCl, 7 mM β-mercaptoethanol), 50 nM biosensor and varied concentrations of
potential inhibitor. Purified Tdp1 was added in a final concentration of 1.5 nM.
The reaction mixtures were incubated at a temperature of 26 ◦C in a POLARstar OPTIMA
fluorimeter, BMG LABTECH, GmbH, Germany, to measure fluorescence intensity every 1 min
(Ex485/Em520 nm). Tdp1 inhibition was calculated by comparing the rate of increase in fluorescence of
biosensor in the presence of compound to that of DMSO (1.5%) control wells. The measurements were
carried out in at least two independent experiments. IC50 values were determined using a six-point
concentration response curve. The data were imported into MARS Data Analysis 2.0 program (BMG
LABTECH) and the slope during the linear phase (here data from 0 to 7 min) was calculated.
2.3.2. Cytotoxicity Assay
Analysis of the toxicity of the compounds was examined against human cell line A-549
(adenocarcinomic human alveolar basal epithelial cells) using a standard MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl-2H-tetrazolium bromide) test [66] by colorimetric measurement of the amount of
formazan converted from MTT in cells exposed to the compounds. The cell line was obtained from the
Russian Cell Culture Collection (RCCC) Institute of Cytology RAS, St. Petersburg, Russia. The cells
were grown in IMDM medium, with 40 µg/mL gentamicin, 50 IU/mL penicillin, 50 µg/mL streptomycin
(MP Biomedicals, Solon, USA) and in the presence of 10% fetal bovine serum (Biolot, Saint Petersburg,
Russia) in 5% CO2 atmosphere. After formation of a 30–50% monolayer, tested compounds were added
to the medium (the volume of added reagents was 1/100 of the total volume of the culture medium, the
amount of DMSO was 1% of the final volume), and the cell culture was monitored for 3 days. Control
cells were grown in the presence of 1% DMSO. The Tdp1 inhibitor concentrations ranged from 1 to
100 µM. Topotecan concentrations ranged from 30 to 3000 nM in the presence of 5 µM Tdp1 inhibitor
or 1% DMSO. The measurements were carried out in three parallel experiments.
2.3.3. Binding Studies
Intrinsic protein fluorescence assay were conducted according to the protocol as described in
references [35,45,49]. The concentrations of recombinant Tdp1 and ligand were 10 µM and 1 mM,
respectively. Excitation wavelength was 280 nm and intrinsic fluorescence was measured between 300
and 450 nm.
Thermal shift assay was carried out using a modified protocol that was described in [67].
Experiments were carried out using an Applied BioSystems QuantStudio 3 Real-Time PCR system.
Samples were measured using 96-well PCR plates (Bio-Rad). Reaction volume was 25 µL. Protein
unfolding was monitored by measuring the fluorescence of the SYPRO Orange dye (Sigma Aldrich, St
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Louis, MO, US). Temperature was increased from 25 to 95 ◦C at 1 ◦C increments every 60 s. The final
concentrations of Tdp1 and compounds were 20 and 100 µM, respectively. Buffer contained 20 mM
Tris (pH 8.0), 250 mM NaCl and 2.5 × SYPRO Orange dye. Measurements were performed in triplicate.
For determination of melting temperature values, melting curve for each data set was analysed by
SigmaPlot 13 (USA) and fitted with the Sigmoid, 3-parameter model.
3. Results and Discussion
3.1. Organic Synthesis
To synthetize amides and thioamides, commercially available 1-adamantane carboxylic acid
chloride 31 was used. An isomeric chloride of 2-adamantane carboxylic acid 32 was obtained
starting from adamantan-2-one 33 according to previously published methods [68–70] including the
synthesis of epoxide 34, its treatment with boron trifluoride etherate and subsequent oxidization
(Scheme 1). 2-Adamantane carboxylic acid 35 was refluxed in thionyl chloride yielding chloride
32 quantitatively. Monoterpene amines 36 and 37 were obtained by Gabriel synthesis. Using this
approach, bromides 40 and 41 were synthesized starting from 3,7-dimethyloctanol 38 and nerol 39,
respectively [42,51]. Then the bromides were stirred with potassium phthalimide at 60 ◦C giving
compounds 42 and 43. Compounds 40 and 41 were purified by column chromatography. Their
interaction with ethylenediamine led to amines 37 and 38. It was found that subsequent dissolving in
hexane and precipitate filtration followed by solvent evaporation led to pure amines (Scheme 1).
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Scheme 1. Synthesis of 2-adamantane carboxylic acid chloride 32 and monoterpene amines 42 and 43.
By interacting chlorides 31 and 32 with amines 36 and 37 a set of amides 44a,b; 45a,b containing
acyclic monoterpenes moieties was synthesized (Scheme 2). The interaction of amides 44a,b; 45a,b
with Lawesson’s reagent led to thioamides 46a,b; 47a,b. For derivative 46b, the isomerization of nerol
fragment during reflux was observed and the resulting mixture contained both citral derivatives
in a trans- and cis-isomers ratio of 1.0:0.8. For structure activity relationship (SAR) studies, the
synthesis of citronellic acid derivatives containing adamantane fragments was performed. Derivative
48 was obtained by refluxing citronellic acid with thionyl chloride. Interaction of 48 with 1- and
2-adamnataneamines 49a,b in the presence of trimethylamine led to amides 50a,b (Scheme 2). Synthesis
of citronellic acid thioamide 51 containing 2-adamantane amine residue was performed by reflux with
Lawesson’s reagent.
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3.2. Inhibition Studies
The binding and inhibition potency of the compounds were tested against purified recombinant
Tdp1. Binding experiments were conducted using thermal shift assay [71] and an intrinsic fluorescence
binding assay that we previously developed [35,45,49]. Thermal shift assay measures the stability
of proteins against thermal degradation. If a molecule binds to the protein, it may be stabilized or
destabilized by the binding of the molecule, thus leading to a shift of the protein melting temperature.
The intrinsic fluorescence binding assay measures the fluorescence intensity of tryptophan residues of
a protein. The active site of Tdp1 is close to several tryptophan residues. Binding of Tdp1 inhibitors
may change the environment of these tryptophan residues, thus leading to quenching of fluorescence
intensity. However, no significant changes in the melting temperature of Tdp1 or quenching of Tdp1
fluorescence intensity were observed (Supplementary Figures S1–S6). This may be due to the low
solubility of our compounds (1 mM or less) in aqueous buffer. As our binding assays typically required
at least tens of µM of Tdp1, we reasoned that the lack of changes in melting temperature and intrinsic
fluorescence intensity are likely due the low ligand-to-protein ratio needed in our experiments, which
did not allow complete formation of Tdp1-inhibitor complex.
Therefore, the inhibition potency of our compounds 44a,b–47a,b; 50a,b; 51 were tested against
Tdp1 by using a biosensor assay previously developed [29]. The biosensor is 16-mer single-stranded
oligonucleotide containing a 5’-FAM (5(6)-carboxyfluorescein) fluorophore donor and a quenching
3’-BHQ1 (Black Hole Quencher-1). Because BHQ1 and FAM are located within the Förster radius,
the fluorescence is quenched. The mechanism of action is based on the Tdp1 enzyme’s ability to
selectively cleave substituents from the 3’-end of DNA [72], thus deriving the Tdp1 activity by
real-time fluorescence detection [29,32]. Table 1 shows the Tdp1 inhibition potency of the compounds
44a,b–47a,b; 50a,b; 51. Furamidine 11, a commercially-available Tdp1 inhibitor, was used as a positive
control. Compounds 46b and 47b were not investigated in Tdp1 inhibitory activity tests due to their
instability. The compounds synthesized can be divided in to two groups: (1) amides and thioamides
of 1- and 2-adamantane carboxylic acids (44a,b; 45a,b; 46a; 47a); (2) derivatives of citronellic acid
(50a,b; 51). Comparing inhibitory activity of the first group (Table 1) and compounds synthesized
previously [49] it can be concluded that amides 44–47 are less active than their ester counterparts are.
For example, in the cases of derivatives 29 (ester), 44 (amide), 48 (thioamide), which are structural
analogues, the following IC50 values were obtained: 0.92, >75 and 3.3 µM, respectively. Note that
derivatives of 2-adamantane carboxylic acid were found to be more active compared to compounds
obtained from 1-admantane carboxylic acid. Thus, amides 44a and 44b were not active, whilst 45a
and 45b showed Tdp1 50% inhibition at 5.2 and 2.5 µM, respectively (Table 1). Comparing amide 45a
and thioamide 47a activity it can be concluded that, for 2-adamantane carboxylic acid derivatives,
oxygen atom replacement by sulphur also led to activity increasing, with IC50 being 5.2 µM for 45a
and 0.64 µM for 47a.
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Similar trends were observed for citronellic acid derivatives 50a,b; 51. For example,
1-aminoadamnatane derivative 50a was not active whilst 2-aminoadamantane 50b activity was
found to be slightly higher and the best IC50 value was obtained for thioamide 51 (2.3 µM), also a
2-aminoadamantane derivative.
Table 1. Tdp1 inhibition potency of the adamantine derivatives.
№
Structure
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IC50, μM 
R1 R2 X 
44a 
  
O >75 
46a 
  
S 3.3 ± 0.5 
(2.8–3.8) * 
45a 
  
O 5.2 ± 0.2 (5.0–5.4) * 
47a 
  
S 0.64 ± 0.17 
(0.47–0.81) * 
44b 
  
O >75 
45b 
  
O 2.5 ± 0.1 
(2.4–2.6) * 
50a 
  
O >75 
50b 
 
O 13.4 ± 3.0 
(10.4–16.4) * 
51 
  
S 
2.3 ± 0.8 
(1.5–3.1)* 
11 Furamidine 1.23 ± 0.33 
(0.90–1.56) * 
* 95% confidence intervals are given in parentheses. 
In general, based on the results shown in Table 1 and previously published results [49], the 
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50a). 
3.3. Cytotoxicity 
The intrinsic cytotoxicity of the adamantane derivatives was examined using the lung 
adenocarcinoma A-549 cell line and the standard MTT assay, the results are shown in Figure S16. In 
general, all the compounds were mildly toxic or non-cytotoxic: CC50 values (cytotoxic concentration 
at 50%) were >80 µM. Since Tdp1 inhibitors are supposed to be used for adjuvant therapy with 
established antitumor drugs, it is important that the Tdp1 therapeutic agents do not cause any side 
effects. 
As already mentioned, the combined use of TOP1 poisons and Tdp1 inhibitors can lead to a 
synergistic effect. Topotecan is a bioavailable derivative of CPT, used in the clinic to treat, for 
example, lung cancer [73]. Despite the important role of topotecan in cancer therapy, resistance to 
CPTs and severe side effects are reported [73]. One of the ways to overcome resistance and/or reduce 
the dose of topotecan, and consequently its toxicity, is the joint use with Tdp1 inhibitors. 
The cytotoxic effect of topotecan was studied in conjunction with the inhibitors. The 
adamantane derivatives were used in the nontoxic concentration of 5 µM. Most compounds had a 
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S 0.64 ± 0.17 
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47a, 50b nd 51) are more activ compared to 1-adamant ne substituted somers (44a, 44b, 46a and 
50a). 
3.3. Cytotoxici y 
The intrins c cytotoxicity of he adamant ne derivatives was examined using the lung 
adenocarcinoma A-549 cell line and the standard MTT assay, the results are shown in Figure S16. In 
general, all the compounds were mildly toxic or non-cyt toxic: CC50 values (cytotoxic concentratio  
at 50%) were >80 µM. Since Tdp1 inhibitors are supposed t  be used for adjuvant therapy with 
established antitumor drugs, it is important that the Tdp1 therapeutic agents do ot cause any side 
effects. 
As already mention d, the combined use of TOP1 poisons and Tdp1 inhibitors can lead to a 
synergistic effect. Topotecan is a bioavailable derivative of CPT, used in the clinic to trea , for 
example, lung cancer [73]. Despite the important role of topotecan in cer therapy, resistance to 
CPTs and severe id  effects ar  reported [73]. One of the ways to overcome esistance and/or re uce 
the dose of topotecan, and conseque tly its toxicity, is the joint use with Tdp1 inhibitors. 
The cytotoxic effect of top tecan was studied in conjun tion w th the inhibitors. The 
adamant ne derivatives wer  used in the nontoxic concentratio  of 5 µM. Most compounds had a 
>75
46a
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In general, based on the results sho n in Table 1 and previously published results [49], the 
follo ing conclusions can be ade: (1) Thioa ides are ore active than the esters and they have 
better activity than their a ide counterparts; (2) 2-ada anatne substituted derivatives (45a, 45b, 
47a, 50b and 51) are ore active co pared to 1-ada antane substituted iso ers (44a, 44b, 46a and 
50a). 
3.3. Cytotoxicity 
The intrinsic cytotoxicity of the ada antane derivatives as exa ined using the lung 
adenocarcino a -549 cell line and the standard TT assay, the results are sho n in Figure S16. In 
general, all the co pounds ere ildly toxic or non-cytotoxic: 50 values (cytotoxic concentration 
at 50 ) ere >80 µ . Since Tdp1 inhibitors are supposed to be used for adjuvant therapy ith 
established antitu or drugs, it is i portant that the Tdp1 therapeutic agents do not cause any side 
effects. 
s already entioned, the co bined use of T P1 poisons and Tdp1 inhibitors can lead to a 
synergistic effect. Topotecan is a bioavailable derivative of PT, used in the clinic to treat, for 
exa ple, lung cancer [73]. espite the i portant role of topotecan in cancer therapy, resistance to 
PTs and severe side effects are reported [73]. ne of the ays to overco e resistance and/or reduce 
the dose of topotecan, and consequently its toxicity, is the joint use ith Tdp1 inhibitors. 
The cytotoxic effect of topotecan as studied in conjunction ith the inhibitors. The 
ada antane derivatives ere used in the nontoxic concentration of 5 µ . ost co pounds had a 
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In general, based on the results shown in Table 1 and previously published results [49], the 
following co clusions can be made: (1) Thioamides are mo active than the es ers and they have 
better ac ivity than their amide counterpar s; (2) 2-adam n tne substit ted derivatives (45a, 45b, 
47a, 50b and 51) are mo active compared to 1-adam ntane substit ted isomer  (44a, 4 b, 46a and 
50a). 
3.3. Cytotoxicity 
The intrinsic cytotoxicity of the adam ntane derivatives was ex mined using the lung
adenocarcinoma A-549 cell lin  and the standard TT assay, the results are shown in Figure S16. In 
general, all the compounds were mildly toxic or non-cyt toxic: CC50 values (cytotoxic c ncentration 
at 50%) were >80 µ . Since Tdp1 inhibitors are upposed t  be used for adjuv nt therapy with 
established antitumor drugs, it is important th t he Tdp1 therapeutic agents do not cause any side 
effects. 
As already mentioned, th  combined us  of TOP1 poisons and Tdp1 inhibitors can lead to  
synergistic effe t. Topotecan is  b oavailable derivative of CPT, used in the clinic to treat, for 
example, lung cancer [73]. Despite the important role of top tecan in cancer therapy, esistance o 
CPTs and evere side ffects are reported [73]. One of th  ways to overcom  resistance and/or reduce 
the dose of top tecan, and co sequently its ox city, is the joint use with Tdp1 inhibitors. 
The cytotoxic effe t of opotecan w s studied in conjunction with the in ibitors. The 
adam ntane derivatives were us d in the ontoxic c ncentration of 5 µ . ost compounds ha  a 
3.3 ± 0.5 (2.8–3.8) *
45a
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following conclusio s can be made: (1) Thioamides are more active than the esters and they have 
better activity than their amide counterparts; (2) 2- d ma atne substituted d ivatives (45a, 45b, 
47a, 50b and 51) are more active compared to 1-adamantane substituted isomers (44a, 44b, 46a and 
50a). 
3.3. Cytotoxicity 
The intrinsic cytotoxicity of the ad mantane deriv tives was examined using th  lung 
ad oc rcinoma A-549 cell line and the standard MTT assay, the results ar  shown in Figure S16. In 
general, all th  compounds w re mildly toxic or non-cytotoxic: CC50 values (cytotoxic concentration 
at 50%) w re >80 µM. Since Tdp1 inhibitors are supposed to be used for adjuvant therapy with 
established antitumor drugs, it is important that the Tdp1 therapeutic agents do not cause any side 
effects. 
As already mentioned, the com ined use of TOP1 pois ns and Tdp1 i hibitors can lead o a 
synergistic effect. Topotecan is a bioavailable derivative of CPT, used i  the clinic to treat, for 
example, lung cancer [73]. Despite the important role of topotecan in anc r ther py, resistance to 
CPTs and severe side effects are r ported [73]. One of the ways to overcome resistance and/or reduce 
the dose of top ecan, and consequently its toxicity, is the joint use wi h Tdp1 inhibitors. 
The cytotoxic effect of topotecan was studied in conju ction with the inhibitors. The 
adamantane derivatives were used in the nontoxic concentration of 5 µM. Most compounds had a 
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In general, based on the results sho n in Table 1 and previ usly published results [49], the 
follo ing co clusions can be ade: (1) Thioa ides are o ctive than the es ers and they have 
better ac ivity than their a ide count rpar s; (2) 2-ada nat e substit ted derivatives ( 5a, 5b, 
47a, 50b and 51) are o active co pared to 1-ada nt ne substit ted iso er  (44a, 4 b, 46a and 
50a). 
3.3. Cytotoxicity 
The i trinsic cytotoxicity of the a a nta e derivative  as ex ined using the lung
adenocarcino a A-549 cell lin  and the stan ard MTT assay, the results are sho n in Figure S16. In 
general, all the co pounds ere ildly toxic or n n-cyt toxic: CC50 values (cytot xic c ncentration 
at 50 ) ere >80 µM. Since Tdp1 inhib tors are uppo ed t  be used for adjuv nt therapy ith 
established antitu or drugs, it is i portant th t he Tdp1 therapeutic agents do not cause any side 
effects. 
As alr ady entioned, th  co bined use of TOP1 poisons and Tdp1 inhibitors can lead to  
synergistic effe t. Topote an is b oavailable deriv tive of CPT, us d in the clinic to treat, for 
exa ple, lung cancer [73]. D spite th  i portant role of t p t can in canc r therapy, esistance o
CPTs and evere side ff ts are rep rted [73]. One of th  ays to overco  resistance and/or educe 
the dose of top te an, and consequently its ox city, i the jo nt use ith Tdp1 i hibitors. 
The cytotoxic effe t of opot can s studied n conjunction ith the in ibitors. The 
ada nt ne derivatives ere us d in the ontoxic c ncentration of 5 µM. Most co pounds ha  a 
5.2 ± 0.2 (5.0–5.4) *
47a
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In general, based on the results sho n in Table 1 and previously published results [49], the 
follo ing conclusions can be ade: (1) Thioa ides are ore active than the esters and they have 
better activity than their a ide counterparts; (2) 2-ada anatne substituted derivatives (45a, 45b, 
47a, 50b and 51) are ore active co pared to 1-ada antane substituted iso ers (44a, 44b, 46a and 
50a). 
3.3. ytotoxicity 
The intrinsic cytotoxicity of the ada antane derivatives as exa ined using the lung 
ade ocarcino a -549 cell line and the standard TT assay, the results are sho n in Figure S16. In 
general, all the co pounds ere ildly toxic or non-cytotoxic: 50 values (cytotoxic concentration 
at 50 ) ere >80 . Since Tdp1 inhibitors are supposed to be used for adjuvant therapy ith 
established antitu or drugs, it is i portant that the Tdp1 therapeutic agents do not cause any side 
effects. 
s already entioned, the co ined use of T P1 poisons and Tdp1 i hibitors can lead to a 
synergistic effect. Topotecan is a bioavailable derivative of PT, used i  the clinic to treat, for 
exa ple, lung cancer [73]. espite the i portant role of topotecan in cancer therapy, resistance to 
PTs and severe side effects are reported [73]. ne of the ays to overco e resistance and/or reduce 
the dose of topotecan, and consequently its toxicity, is the joint use ith Tdp1 inhibitors. 
The cytotoxic effect of topotecan as studied in conju ction ith the inhibitors. The 
ada antane derivatives ere used in the nontoxic concentration of 5 . ost co pounds had a 
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 t t i  ff t  t t  w s st i  i  j ti  wit t  i i it rs.  
ma t  ri ti s w r  s  i  t  t i  tr ti  f  . st m s d  
S 0.64 ± 0.17(0.47–0.81) *
44b
ppl. Sci. 2019, 9, x FOR PEER RE IEW 12 of 19 
able 1. Tdp1 inhibition potency of the adamantine derivatives. 
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tr ct re 
 
IC50, μM 
R1 R2 X 
44a 
  
O >75 
46a 
  
S 3.3 ± 0.5 
(2.8–3.8) * 
45a 
  
O 5.2 ± 0.2 (5.0–5.4) * 
47a 
  
S 0.64 ± 0.17 
(0.47–0.81) * 
44  
  
O >75 
45  
  
O 2.5 ± 0.1 
(2.4–2.6) * 
50a 
  
O >75 
50  
 
O 13.4 ± 3.0 
(10.4–16.4) * 
51 
  
S 
2.3 ± 0.8 
( .5–3.1)* 
11 F rami i e 1.23 ± 0.33 
(0.90–1.56) * 
* 95% confidence intervals are given in parentheses. 
I  ge eral, base  o  t e res lts s ow  i  able 1 a  re io sly blis e  res lts [49], t e 
followi g co cl sio s ca  be ma e: (1) ioami es are more acti e t a  t e esters a  t ey a e 
better acti ity t a  t eir ami e co ter arts; (2) 2-a ama at e s bstit te  eri ati es (45a, 45 , 
47a, 50  a  51) are more acti e com are  to 1-a ama ta e s bstit te  isomers (44a, 44 , 46a a  
50a). 
3.3. Cytotoxicity 
e i tri sic cytotoxicity of t e a ama ta e eri ati es was exami e  si g t e l g 
a enocarci oma A-549 cell li e a  t e sta ar  M  assay, t e res lts are s ow  i  Fig re S16. I  
ge eral, all t e com o s were mil ly toxic or o -cytotoxic: CC50 al es (cytotoxic co ce tratio  
at 50%) were >80 µM. Si ce 1 i ibitors are s ose  to be se  for a j a t t era y wit  
establis e  a tit mor r gs, it is im orta t t at t e 1 t era e tic age ts o ot ca se a y si e 
effects. 
As alrea y me tio e , t e combi e  se of O 1 oiso s a  1 in ibitors ca  lea  to a 
sy ergistic effect. o oteca  is a bioa ailable eri ati e of C , se  in t e cli ic to treat, for 
exam le, l g ca cer [73]. Des ite t e im orta t role of to oteca  i  ca cer t era y, resista ce to 
C s a  se ere si e effects are re orte  [73]. O e of t e ways to o ercome resista ce a /or re ce 
t e ose of to oteca , a  co seq e tly its toxicity, is t e joi t se wit  1 i ibitors. 
e cytotoxic effect of to oteca  was st ie  i  co j nctio  wit  t e i ibitors. e 
a ama ta e eri ati es were se  i  t e o toxic co ce tratio  of 5 µM. Most com o s a  a 
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R1 R2 X 
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O >75 
46a 
  
S 3.3 ± 0.5 
(2.8–3.8) * 
45a 
  
O 5.2 ± 0.2 (5.0–5.4) * 
47a 
  
S 0.64 ± 0.17 
(0.47–0.81) * 
44b 
  
O >75 
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O 2.5 ± 0.1 
(2.4–2.6) * 
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O 13.4 ± 3.0 
(10.4–16.4) * 
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S 
2.3 ± 0.8 
(1.5–3.1)* 
11 Furamidine 1.23 ± 0.33 
(0.90–1.56) * 
* 95% confiden e intervals ar  given in par theses. 
In general, based on the results shown in Table 1 and previously published re ults [49], he 
following c nclusions can be made: (1) Thioamides re more active than the esters and they have 
better activity than their amide count rparts; (2) 2-adaman tne substituted derivativ s (45a, 45b, 
47a, 50b and 51) re more active compared to 1-a amantane substituted isom rs (44a, 44b, 46a and 
50a). 
3.3. Cytotoxicity 
The intrinsic cytotoxi ity f the adamantane derivativ s was examined usi g the lung 
adenocarcinom  A-549 cell line and th  standard MTT assay, the results are shown in Figure S16. In 
general, all the compounds were mildly toxic or non-cytot xi : CC50 values (cytotoxi  c ncentration 
at 50%) were >80 µM. Since Tdp1 inhibitors are supposed to be used for adjuvant ther py with 
established antitumor drugs, it is important tha  the Tdp1 thera eutic g n s do not cause any side 
effects. 
As already m ntioned, he combined use of TOP1 poisons and Tdp1 inhibitors can lead to a 
synergistic ffec . Topotecan is a bioav ilable derivativ  of CPT, used in the clinic to treat, for 
example, lung cancer [73]. Despite the important r le of topotecan in cancer therapy, r sistanc  to 
CPTs and severe side ffects are report d [73]. One of the ways to overcome resistanc  and/or reduce 
the dose of topotecan, and consequently its toxic y, is the joint use wi h Tdp1 inhibitors. 
The cytotoxi  effect of topotecan was studied in conju cti  wi h the inhibitors. The 
adamantane derivativ s were used in th  non oxic concentration of 5 µM. Most compounds had a 
O >75
45b
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etter activity than their a ide counterp rts; (2) 2-ada anatne substituted derivatives (45a, 45b, 
47a, 50b and 51) are ore active co pared to 1-ada antane substituted iso ers (44a, 44b, 46a and 
50a). 
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The intrinsic cytotoxicity of the ada antane derivatives was exa ined using the lung 
adenocarcino a A-549 cell line and the standard TT assay, the results are show  in Figure S16. In 
general, all the co poun s were ildly toxic or non-cytotoxic: CC50 v lues (cytotoxic concentration 
at 50%) were >80 µ . Since Tdp1 inhibitors are supposed to be used for a juvant therapy with 
established antitu or drugs, it is i portant that the Tdp1 therapeutic agents do not cause any side 
effects. 
As already entioned, the co bine  use of TOP1 poisons and T p1 i hibitors can lead to a 
synergistic effect. Topotecan is a bi available derivative of CPT, used in the clinic to treat, for 
exa ple, lung cancer [73]. Despite the i portant role of t potecan in cancer therapy, resistance to 
CPTs and severe si e effects are reported [73]. One of the ways to overco e resistance and/or reduce 
the dose of topotecan, and consequently its toxicity, is the joint use it  Tdp1 i i it rs. 
The cytotoxic effect of topotecan was studied in conjunction with the inhibitors. The 
ada antane derivatives were used in the nontoxic concentration of 5 µ . ost co pounds had a 
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lung cancer [73]. Despite the important role of topotecan in cancer therapy, resistance to CPTs and
severe side effects are reported [73]. One of the ways to overcome resistance and/or reduce the dose of
topotecan, and consequently its toxicity, is the joint use with Tdp1 inhibitors.
The cytotoxic effect of topotecan was studied in conjunction with the inhibitors. The adamantane
derivatives were used in the nontoxic concentration of 5 µM. Most compounds had a weak or no
sensitizing effect (data not shown). The most pronounced was by compound 46a (Figure 3), thioamide
of 2-adamantane carboxylic acid with 3,7-dimethyloctane fragment.
Appl. Sci. 2019, 9, x FOR PEER REVIEW 13 of 19 
weak or no sensitizing effect (data not shown). The most pronounced was by compound 46a (Figure 
3), thioamide of 2-adamantane carboxylic acid with 3,7-dimethyloctane fragment. 
0 500 1000 1500 2000 2500 3000
20
40
60
80
100
120
A-
54
9 c
ell
s v
iab
ilit
y, 
%
Topotecan, nM
 Topotecan + DMSO
 Topotecan + 46a
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The eleven molecules were docked into the binding site of Tdp1 (PDB ID: 1MU7, resolution 2.0 
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docked. The modelling shows that all the ligands show a similar plausible binding mode for both 
scenarios. The ligands have higher scores with water (see Table S1), which suggests that they 
contribute to the stability of the protein and binding. Indeed, the modelling predicts that the ligands 
interact with the water molecules. For the most interesting compound 46a, the sulphur atom forms 
an H-bond with HOH631, this water molecule also interacts with Thr261, forming an H-bond bridge 
between the ligand the protein. The second water molecule HOH832 does not form direct H-bonds 
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values lie in the range of 4.4 and 6.3. The ligands have low PSA values between 13.3 and 33.9. The 
known drug indexes 2a and 2b (KDIs2a/2b) [75] were also derived. The KDIs reflect the overall balance 
of the molecular properties of ligands based on KDS. KDI2a is additive with a maximum of 6.0 and 
for KDI2b the indexes are multiplied giving 1.0 as its maximum. The average for KDI2a for known 
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Figure 3. Dose-dependent action of topotecan in combination with 5 µM of 46a on A-549 cells viability.
Therefore, 46a is the most promising derivative as it has high enough anti-Tdp1 activity, low
cytotoxicity and synergism with topotecan.
3.4. Molecular Modeling
The eleven molecules were docked into the binding site of Tdp1 (PDB ID: 1MU7, resolution
2.0 Å) [53] with reasonable scores, as shown in Table S1 in the supplementary materials. Furthermore,
two water molecules (H2O631 and H2O832) were kept in the binding pocket and all the ligands docked.
The modelling shows that all the ligands show a similar plausible binding mode for both scenarios.
The ligands have higher scores with water (see Table S1), which suggests that they contribute to the
stability of the protein and binding. Indeed, the modelling predicts that the ligands interact with the
water molecules. For the most interesting compound 46a, the sulphur atom forms an H-bond with
HOH631, this water molecule also interacts with Thr261, forming an H-bond bridge between the
ligand the protein. The second water molecule HOH832 does not form direct H-bonds with the ligand
but nudges the adamantane moiety closer to a lipophilic region. The adamantane moiety occupies a
relatively lipophilic portion of the binding pocket whilst the thioamide occupies a hydrophilic portion
as shown with Figure 4A.
The calculated molecular descriptors molecular weight (MW), number of hydrogen bond donors
(HDs), number of hydrogen bond acceptors (HAs), lipophilicity (Log P), polar surface area (PSA) and
number of rotatable bonds (RBs) are given in Table S2 in the supplementary materials. HDs, HAs, and
PSA are within the lead-like chemical space for all the ligands whilst the molecules have MW within the
drug-like chemical space. The molecules are within the drug-like and known drug space (KDS) for Log
P. The RBs are within the drug-like chemical space (for the definition of lead-like, drug-like and KDS
regions see [54] and Table S3). Interestingly, it has been shown recently that orally bioavailable drugs
tend not to follow the drug-like definition, in particular when it comes to MW [74]. The molecular
weight of the ligands is between 303.5 and 335.6 g mol-1 and the Log P values lie in the range of 4.4
and 6.3. The ligands have low PSA values between 13.3 and 33.9. The known drug indexes 2a and 2b
(KDIs2a/2b) [75] were also derived. The KDIs reflect the overall balance of the molecular properties
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of ligands based on KDS. KDI2a is additive with a maximum of 6.0 and for KDI2b the indexes are
multiplied giving 1.0 as its maximum. The average for KDI2a for known drugs is 4.08 (±1.27) and the
ligands lie in the range of 4.58 to 5.23 (i.e., they are well balanced compared to known drugs). The
KDI2b gives a range of 0.18 to 0.43 with the average of know drugs being 0.18 (±0.20). The relatively
low values can be attributed to the high Log Ps of 46a and 47a. The KDI2b index is less forgiving, since
on one low number sinks the index significantly due to its multiplicative nature. Nevertheless, the
ligands are relatively well balanced.
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Figure 4. The docked configuration of 46a in the binding site of Tdp1 as predicted using the 
ChemScore scoring function. (A) The protein surface is rendered. The ligand occupies the binding 
pocket. Blue depicts a hydrophilic region on the surface; brown depicts hydrophobic region and 
whites shows neutral areas. (B) H-bonds are shown as dotted green lines between the sulphur atom 
and HOH631. The water molecules also form H-bonds with Thr261 and Asn516. 
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Previously, a family of esters functionalised with monoterpene and adamantine moieties was 
found to be good inhibitors of Tdp1. Esters are known to be labile (i.e., hydrolyse relatively easily at 
physiological conditions, rendering compounds containing esters potentially problematic as drug 
candidates). We; therefore, substituted the ester bridge with amide and thioamide groups and tested 
them against Tdp1. Derivative 46a stood out as the most promising candidate as it synergised with 
topotecan, a Top1 poison in clinical use against cancer, only at 5 µM, which is a fully non-toxic dose. 
The reported IC50 value is 3.3 µM, which is not the lowest of the series synthesised, but interestingly 
on 46a showed synergy with topotecan in the cancer cell line used (A-549 lung adenocarcinoma. 
According to molecular modelling, a good fit is predicted for 46a into the substrate pocket of Tdp1, 
inhibiting its activity.  
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containing 20 mM Tris (pH 8.0) and 250 mM NaCl. Control experiments were conducted with DMSO, which is 
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neutral areas. (B) H-bonds are shown as dotted green lines betwee the sulphur atom and HOH631.
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4. Conclusions
Previously, a family of esters functionalised with monoterpene and adamantine moieties was
found to be good inhibitors of Tdp1. Esters are known to be labile (i.e., hydrolyse relatively easily
at physiological conditions, rendering compounds containing esters potentially problematic as drug
candidates). We; therefore, substituted the ester bridge with amide and thioamide groups and tested
them against Tdp1. Derivative 46a stood out as the most promising candidate as it synergised with
topotecan, a Top1 poison in clinical use against cancer, only at 5 µM, which is a fully non-toxic dose. The
reported IC50 value is 3.3 µM, which is not the lowest of the series synthesised, but interestingly on 46a
showed synergy with topotecan in the cancer cell line used (A-549 lung adenocarcinoma. According
to molecular modelling, a good fit is predicted for 46a into the substrate pocket of Tdp1, inhibiting
its activity.
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T calculated molecular descriptors for the ligands; Table S3: Definition of lead-like, drug-like and known
drug space (KDS) in terms of molecular descriptors. The values given are the maxima for each descriptor for
the volumes of chemical space used; Figure S1: Intrinsic fluorescence spectroscopy of Tdp1 in the presence of
compounds 45, 45a 46a, 47a and 51. Samples contained 10 µM Tdp1 and 1 mM compound (if applicable) dissolved
in a buffer containing 20 mM Tris (pH 8.0) and 250 mM NaCl. Control experiments were conducted with DMSO,
which is the solvent that the compounds were dissolved in. Excitation wavelength was 280 nm and intrinsic
fluorescence was mea ured between 3 0 and 450 nm. Maximum fluoresc nce i tensity as reported. Ot er
compounds were not tested because they are not soluble at the required concentration in aqueous buffer; Figure S2:
Protein melt curves showing the denaturing temperature of Tdp1 (10 µM, red) and Tdp1 (10 µM) in the presence
of compound 44b (100 µM, blue) as monitored by thermal shift assay. Buffer was 20 mM Tris (pH 8.0) and 250 mM
NaCl. Changes in denaturing temperature were found to be −0.27 ◦C; Figure S3: Protein melt curves showing the
denaturing temperature of Tdp1 (10 µM, red) and Tdp1 (10 µM) in the presence of compound 45a (100 µM, blue)
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temperature were found to be 0.04 ◦C; Figure S4: Protein melt curves showing the denaturing temperature of
Tdp1 (10 µM, red) and Tdp1 (10 µM) in the presence of compound 46a (100 µM, blue) as monitored by thermal
shift assay. Buffer was 20 mM Tris (pH 8.0) and 250 mM NaCl. Changes in denaturing temperature were found
to be −0.1 ◦C; Figure S5: Protein melt curves showing the denaturing temperature of Tdp1 (10 µM, red) and
Tdp1 (10 µM) in the presence of compound 47a (100 µM, blue) as monitored by thermal shift assay. Buffer was
20 mM Tris (pH 8.0) and 250 mM NaCl. Changes in denaturing temperature were found to be 0.08 ◦C; Figure S6:
Protein melt curves showing the denaturing temperature of Tdp1 (10 µM, red) and Tdp1 (10 µM) in the presence
of compound 51 (100 µM, blue) as monitored by thermal shift assay. Buffer was 20 mM Tris (pH 8.0) and 250 mM
NaCl. Changes in denaturing temperature were found to be −0.22 ◦C; Figures S7–15: 1H NMR spectra of the
products; Figure S16: Dose-dependent influence of the adamantane derivatives on A-549 cell viability using the
MTT assay.
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